Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to UB-VV111 for the treatment of ...
Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.
Blood Cancer United, which was formerly known as the Leukemia & Lymphoma Society, has created a way for blood cancer patients ...
A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track ...
Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...
Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...
Analysis of readmission rates, length of stay and mortality among bone marrow transplant and CAR-T patients in a rural state. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback